A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03119428 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 18, 2017
Last Update Posted : December 7, 2018
|
Sponsor:
OncoMed Pharmaceuticals, Inc.
Information provided by (Responsible Party):
OncoMed Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent or in combination with nivolumab. OMP-313M32 is an experimental anti-TIGIT antibody that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy cancer cells.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Locally Advanced Cancer Metastatic Cancer | Drug: OMP-313M32 Drug: Nivolumab | Phase 1 |
This is an open-label, Phase 1a/b dose escalation study of OMP-31M32 administered as a single agent or in combination with nivolumab to evaluate the safety, tolerability pharmacokinetics, and pharmacodynamics in patients with locally advanced or metastatic solid tumors. This study consists of a screening period, a treatment period and a post-treatment follow-up period in which patients will be followed for survival for up to 2 years. Subjects will be enrolled in two stages in the Phase 1a (dose escalation and expansion) and one stage in the Phase 1b (dose escalation).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 30 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1a/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent or in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors |
| Actual Study Start Date : | May 2, 2017 |
| Estimated Primary Completion Date : | May 2019 |
| Estimated Study Completion Date : | October 2019 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Nivolumab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: OMP-313M32
Intravenous (in the vein) infusions of OMP-313M32 as a single agent
|
Drug: OMP-313M32
OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
Other Name: Anti-TIGIT monoclonal antibody |
|
Experimental: OMP-313M32 and Nivolumab
Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
|
Drug: OMP-313M32
OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
Other Name: Anti-TIGIT monoclonal antibody Drug: Nivolumab Human IgG4 anti-PD-1 monoclonal antibody
Other Name: Opdivo |
Primary Outcome Measures :
- Incidence of dose limiting toxicities (DLTs) [ Time Frame: Subjects will be assessed for DLTs through the end of the first cycle (Days 1-29) ]The Maximum tolerated dose (MTD) or maximum administered dose (MAD) will be determined in patients treated with OMP-313M32 in combination with nivolumab
- Incidence of treatment emergent adverse events [ Time Frame: up to approximately 2 years ]Percentage of patients with adverse events
Secondary Outcome Measures :
- Pharmacokinetic Outcome Measures (AUC) - Phase 1a [ Time Frame: 1st dose and 4th dose: pre-dose, post-infusion, and 1, 3, 7 and 10 days. All other doses: pre-dose, 15 minutes and 7 days post-infusion. PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]Area under the plasma concentration versus time curve (AUC) will be evaluated
- Pharmacokinetic Outcome Measures (AUC) - Phase 1b [ Time Frame: 1st dose and 4th dose: pre-dose and 15 minutes post-infusion. All other doses: pre-dose. PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]Area under the plasma concentration versus time curve (AUC) will be evaluated
- Pharmacokinetic Outcome Measures (T1/2) - Phase 1a [ Time Frame: 1st dose and 4th dose: pre-dose, post-infusion, and 1, 3, 7 and 10 days. All other doses: pre-dose, 15 minutes and 7 days post-infusion. PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]The half life (T1/2) of OMP-313M32 will be assessed
- Pharmacokinetic Outcome Measures (T1/2) - Phase 1b [ Time Frame: 1st dose and 4th dose: pre-dose and 15 minutes post-infusion. All other doses, pre-dose.PK sample will be taken at treatment termination and every 4 wks for 12 wks. ]The half life (T1/2) of OMP-313M32 will be assessed
- Immunogenicity of OMP-313M32 [ Time Frame: up to approximately 2 years ]Percentage of patients with anti-OMP-313M32 antibodies assessed
- Objective Response [ Time Frame: up to approximately 2 years ]Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- Progression-free survival [ Time Frame: approximately 2 years ]Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologic documentation of locally advanced, recurrent or metastatic solid malignancy that has progressed and standard therapy has been ineffective or intolerable. Phase 1b subjects must also have experienced disease progression after treatment with an anti PD-1 or PDL-1 agent.
- Ability to understand the willingness and to sign a written informed consent document
- Age >/= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy >/=12 weeks
- Measurable disease per response evaluation criteria in solid tumors.
- Adequate hematologic and organ function
- For women of childbearing potential and men with partners of childbearing potential, agreement (by patient and/or partner) to use two effective forms of contraception from study entry through at least 6 months after the termination visit.
Exclusion Criteria:
- Anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks or 5 half lives, whichever is shorter, prior to initiation of study treatment
- Active autoimmune disease or a history of severe autoimmune disease or syndrome
- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
- Inability to comply with study and follow-up procedures.
- Pregnancy, lactation, or breastfeeding women.
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina.
- Known clinically significant liver disease,
- Major surgical procedure within 28 days prior to initiation of study treatment or anticipation of need for a major surgical procedure during the course of the study.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03119428
Locations
| United States, Arizona | |
| Scottsdale | |
| Scottsdale, Arizona, United States, 85258 | |
| United States, North Carolina | |
| Durham | |
| Durham, North Carolina, United States, 27710 | |
| United States, Oklahoma | |
| Oklahoma | |
| Oklahoma City, Oklahoma, United States, 73104 | |
| United States, Tennessee | |
| Nashville | |
| Nashville, Tennessee, United States, 37203 | |
| United States, Utah | |
| Salt Lake City | |
| Salt Lake City, Utah, United States, 84112 | |
Sponsors and Collaborators
OncoMed Pharmaceuticals, Inc.
| Responsible Party: | OncoMed Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT03119428 History of Changes |
| Other Study ID Numbers: |
313M32-001 |
| First Posted: | April 18, 2017 Key Record Dates |
| Last Update Posted: | December 7, 2018 |
| Last Verified: | June 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Additional relevant MeSH terms:
|
Neoplasm Metastasis Neoplastic Processes Neoplasms Pathologic Processes Antibodies |
Antibodies, Monoclonal Nivolumab Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents |